UK stocks fall, dragged down by industrials; Powell speech in focus
BY Reuters | ECONOMIC | 12/01/25 12:38 PM EST*
FTSE 100 down 0.2%, FTSE 250 down 0.7%
*
Melrose slides, names new CFO
*
US announces zero tariff pharmaceutical deal with Britain
(Updates after markets close)
Dec 1, 2025 - UK stocks dipped on Monday, dragged down by losses in industrials stocks, amid a general risk-off global sentiment across markets, with investors monitoring domestic data sets and the U.S. Federal Reserve monetary path.
The blue-chip FTSE 100 ended down 0.2%. The domestically focused FTSE 250 lost 0.7%, logging its biggest one-day drop in two weeks.
Aerospace and defence stocks led sectoral losses, down 2.8%. Melrose, which announced a new CFO, fell 4.6%, while Rolls-Royce and BAE Systems lost 2.9% and 2.5%, respectively.
U.S. and Ukrainian officials held talks on Sunday regarding a peace deal with Russia, with Secretary of State Marco Rubio optimistic about progress toward ending the more than three-year war.
Homebuilders fell 1.3%, with Barratt Redrow
On the flip side, precious metal mining stocks added 4.9%, tracking gold prices that rose to a six-week high. Fresnillo rose 7.1% to hit a record high, while Hochschild Mining climbed 3.7%.
Industrial miners gained 1.1% with Anglo
American and Antofagasta
Meanwhile, domestic data showed that Britain's services sector declined at the fastest pace in three years in the three months to November, while a Bank of England policymaker said more signs of weakening labour market is required for a rate cut in December.
Separately, the manufacturing PMI increased for the first time last month since September 2024, a survey showed.
Across the Atlantic, U.S. Fed Chair Jerome Powell's speech later in the day will be scrutinized for fresh clues on the interest rate path.
Among other stocks, Reckitt rose 2.4% after a
Barclays upgrade. HICL Infrastructure
Additionally, the U.S. and Britain announced a deal to secure zero tariffs on British pharmaceutical products and medical technology in return for Britain spending more on medicines and overhauling how it values drugs. (Reporting by Utkarsh Tushar Hathi Editing by Vijay Kishore and Frances Kerry)
Print
